GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revolution Medicines Inc (FRA:42Z) » Definitions » Capex-to-Operating-Income

Revolution Medicines (FRA:42Z) Capex-to-Operating-Income : 0.00 (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Revolution Medicines Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Revolution Medicines's Capital Expenditure for the three months ended in Dec. 2024 was €-1.17 Mil. Its Operating Income for the three months ended in Dec. 2024 was €-206.58 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Revolution Medicines Capex-to-Operating-Income Historical Data

The historical data trend for Revolution Medicines's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revolution Medicines Capex-to-Operating-Income Chart

Revolution Medicines Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial - - - - -

Revolution Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Revolution Medicines's Capex-to-Operating-Income

For the Biotechnology subindustry, Revolution Medicines's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revolution Medicines's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Revolution Medicines's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Revolution Medicines's Capex-to-Operating-Income falls into.


;
;

Revolution Medicines Capex-to-Operating-Income Calculation

Revolution Medicines's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-9.844) / -658.495
=N/A

Revolution Medicines's Capex-to-Operating-Income for the quarter that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-1.167) / -206.576
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revolution Medicines  (FRA:42Z) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Revolution Medicines Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Revolution Medicines's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Revolution Medicines Business Description

Traded in Other Exchanges
Address
700 Saginaw Drive, Redwood City, CA, USA, 94063
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines Headlines

No Headlines